Information Provided By: 
Fly News Breaks for February 28, 2020
NEO
Feb 28, 2020 | 07:29 EDT
Benchmark analyst Bruce Jackson raised the firm's price target on NeoGenomics to $30 from $27 and keeps a Buy rating on the shares after the company reported better than expected Q4 results. He also said the company's 2020 revenue guidance was "essentially in-line" after factoring in the acquisition of the Oncology Division lab business of Human Longevity. He would use any share price weakness to accumulate NeoGenomics shares, Jackson added.
News For NEO From the Last 2 Days
There are no results for your query NEO
